Plasma protein S residues 37–50 mediate its binding to factor Va and inhibition of blood coagulation

Summary

Protein S (PS) is an anticoagulant plasma protein whose deficiency is associated with increased risk of venous thrombosis. PS directly inhibits thrombin generation by the blood coagulation pathways by several mechanisms, including by binding coagulation factors (F) Va and Xa. To identify PS sequences that mediate inhibition of FVa activity, antibodies and synthetic peptides based on PS sequence were prepared and employed in plasma coagulation assays, purified component prothrombinase assays, binding assays, and immunoblots. In the absence of activated protein C, monoclonal antibody (Mab) S4 shortened FXa-induced clotting in normal plasma but not in PS-depleted plasma. Mab S4 also blocked PS inhibition of FVa-dependent prothrombinase activity in purified component assays in the absence or presence of phospholipids and inhibited binding of PS to immobilised FVa. Epitope mapping identified N-terminal region residues 37–67 of PS as this antibody’s epitope. A peptide representing PS residues 37–50 inhibited FVa-dependent prothrombinase activity in a noncompetitive manner, with 50% inhibition observed at 11 µM peptide, whereas a peptide with a D-amino acid sequence of 37–50 was ineffective. FVa, but not FXa, bound specifically to the immobilised peptide representing residues 37–50, and the peptide inhibited binding of FVa to immobilised PS. These data implicate PS residues 37–50 as a binding site for FVa that mediates, at least in part, the direct inhibition of FVa-dependent procoagulant activity by PS.

Keywords

Anticoagulant - factor Va - monoclonal antibody - peptide - protein S - structure-function relationship

• References

• 1 Burstyn-Cohen T, Heeb MJ, Lemke G. Lack of Protein S in mice causes embryonic lethal coagulopathy and vascular dysgenesis. J Clin Invest 2009; 119: 2942-2953.
• 2 Saller F, Brisset AC, Tchaikovski SN, Azevedo M. et al. Generation and phenotypic analysis of protein S-deficient mice. Blood 2009; 114: 2307-2314.
• 3 Mahasandana C, Suvatte V, Marlar RA. et al. Neonatal purpura fulminans associated with homozygous protein S deficiency. Lancet 1990; 335: 61-62.
• 4 Schwarz HP, Fischer M, Hopmeier P. et al. Plasma protein S deficiency in familial thrombotic disease. Blood 1984; 64: 1297-1300.
• 5 Mahmoodi BK, Brouwer JL, Veeger NJ. et al. Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age: results from a large family cohort study. Circulation 2008; 118: 1659-1667.
• 6 Comp PC, Esmon CT. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 1984; 311: 1525-1528.
• 7 Walker FJ. Protein S and the regulation of activated protein C. Semin Thromb Hemost 1984; 10: 131-138.
• 8 Griffin JH, Zlokovic BV, Mosnier LO. Protein C anticoagulant and cytoprotective pathways. Int J Hematol 2012; 95: 333-345.
• 9 Heeb MJ, Mesters RM, Tans G. et al. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem 1993; 268: 2872-2877.
• 10 Heeb MJ, Rosing J, Bakker HM. et al. Protein S binds to and inhibits factor Xa. Proc Natl Acad Sci USA 1994; 91: 2728-2732.
• 11 Fernandes NL, Mosnier LO, Tonnu L. et al. Zinc-containing protein S inhibits extrinsic factor X activating complex independently of tissue factor pathway inhibitor. J Thromb Haemost 2010; 08: 1976-1985.
• 12 Hackeng TM, van't Veer C, Meijers JCM. et al. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem 1994; 269: 21051-21058.
• 13 Schwarz HP, Heeb MJ, Wencel-Drake JD. et al. Identification and characterization of protein S in human platelets. Blood 1985; 66: 1452-1455.
• 14 Stavenuiter F, Davis NF, Duan E. et al. Platelet protein S directly inhibits procoagulant activity on platelets and microparticles. Thromb Haemost 2013; 109: 229-237.
• 15 Heeb MJ, Marzec U, Gruber A. et al. Antithrombotic activity of protein S infused without activated protein C in a baboon thrombosis model. Thromb Haemost 2012; 107: 690-698.
• 16 Hackeng T, Sere KM, Tans G. et al. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci USA 2006; 103: 3106-3111.
• 17 Yegneswaran S, Hackeng TM, Dawson PE. et al. The thrombin-sensitive region of protein S mediates phospholipid-dependent interaction with factor Xa. J Biol Chem 2008; 283: 33046-33052.
• 18 Stenberg Y, Muranyi A, Steen C. et al. EGF-like module pair 3-4 in vitamin K-dependent protein S: modulation of calcium affinity of module 4 by module 3, and interaction with factor X. J Mol Biol 1999; 293: 653-665.
• 19 Heeb MJ, Kojima Y, Tans G. et al. C-terminal residues 621-635 of protein S are essential for binding to factor Va. J Biol Chem 1999; 274: 36187-36192.
• 20 Heeb MJ, Prashun D, Griffin JH. et al. Plasma protein S contains zinc essential for efficient activated protein C-independent anticoagulant activity and binding to factor Xa, but not for efficient binding to tissue factor pathway inhibitor. FASEB J 2009; 23: 2244-2253.
• 21 Tans G, Rosing J, Thomassen MC. et al. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood 1991; 77: 2641-2648.
• 22 Fernandez JA, Heeb MJ, Xu X. et al. Species-specific anticoagulant and mitogenic activities of murine protein S. Haematologica 2009; 94: 1721-1731.
• 23 Heeb MJ, Koenen RR, Fernandez JA. et al. Direct anticoagulant activity of protein S-C4b binding protein complex in Heerlen heterozygotes and normals. J Thromb Haemost 2004; 02: 1766-1773.
• 24 Heeb MJ, Griffin JH. Activated Protein C-dependent and -independent Anticoagulant Activities of Protein S have Different Structural Requirements. Blood Cells Mol Dis 2002; 29: 190-199.
• 25 Rosing J, Tans G, Govers-Riemslag JWP. et al. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem 1980; 255: 274-283.
• 26 Saller F, Villoutreix BO, Amelot A. et al. The gamma-carboxyglutamic acid domain of anticoagulant protein S is involved in activated protein C cofactor activity, independently of phospholipid binding. Blood 2005; 105: 122-130.
• 27 Stavenuiter F, Gale AJ, Heeb MJ. Phosphorylation of protein S by platelet kinases enhances its activated protein C cofactor activity. FASEB J. 2013 27. in press.
• 28 Rezende SM, Lane DA, Mille-Baker B. et al. Protein S Gla-domain mutations causing impaired Ca(2+)-induced phospholipid binding and severe functional protein S deficiency. Blood 2002; 100: 2812-2819.
• 29 Ikejiri M, Tsuji A, Wada H. et al. Analysis three abnormal Protein S genes in a patient with pulmonary embolism. Thromb Res 2010; 125: 529-532.
• 30 Neki R, Fujita T, Kokame K. et al. Genetic analysis of patients with deep vein thrombosis during pregnancy and postpartum. Int J Hematol 2011; 94: 150-155.
• 31 Ahnstrom J, Andersson HM, Canis K. et al. Activated protein C cofactor function of protein S: a novel role for a gamma-carboxyglutamic acid residue. Blood 2011; 117: 6685-6693.
• 32 Garcia de FP, Fuentes-Prior P, Hurtado B. et al. Molecular basis of protein S deficiency. Thromb Haemost 2007; 98: 543-556.
• 33 Villoutreix BO, Teleman O, Dahlback B. A theoretical model for hte Gla-TSREGF-1 region of the anticoagulant cofactor protein S: from biostructural pathology to species-specific cofactor activity. J Comput Aided Mol Des 1997; 11: 293-304.
• 34 He X, Shen L, Villoutreix BO. et al. Amino acid residues in thrombin-sensitive region and first epidermal growth factor domain of vitamin K-dependent protein S determining specificity of the activated protein C cofactor function. J Biol Chem 1998; 273: 27449-27458.
• 35 Giri TK, de Frutos PG, Yamazaki T. et al. In vitro characterisation of two naturally occurring mutations in the thrombin-sensitive region of anticoagulant protein S. Thromb Haemost 1999; 82: 1627-1633.
• 36 Gandrille S, Borgel D, Ireland H. et al. Protein S deficiency: a database of mutations. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1997; 77: 1201-1214.
• 37 Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994; 269: 18735-18738.
• 38 Cramer TJ, Griffin JH, Gale AJ. Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va. Pathophysiol Haemost Thromb 2010; 37: 17-23.
• 39 Hayashi T, Nishioka J, Suzuki K. Molecular mechanism of the dysfunction of protein S (Tokushima) (Lys155-- >Glu) for the regulation of the blood coagulation system. Biochim Biophys Acta 1995; 1272: 159-167.
• 40 Heeb MJ, Kojima Y, Hackeng TM. et al. Binding sites for blood coagulation factor Xa and protein S involving residues 493-506 in factor Va. Protein Sci 1996; 05: 1883-1889.
• 41 Solymoss S, Tucker MM, Tracy PB. Kinetics of inactivation of membrane-bound factor Va by activated protein C: Protein S modulates factor Xa protection. J Biol Chem 1988; 263: 14884-14890.
• 42 Heeb MJ, Radtke K-P, Fernandez JA. et al. Plasma contains protein S monomers and multimers with similar direct anticoagulant activity. J Thromb Haemost 2006; 04: 2215-2222.